Abstract:Accumulating evidence indicates that abnormal deposition of amyloid‐β (Aβ) peptide in the brain is responsible for endothelial cell damage and consequently leads to blood–brain barrier (BBB) leakage. However, the mechanisms underlying BBB disruption are not well described. We employed an monolayer BBB model comprising bEnd.3 cell and found that BBB leakage was induced by treatment with Aβ1–42, and the levels of tight junction (TJ) scaffold proteins (ZO‐1, Claudin‐5, and Occludin) were decreased. Through comparisons of the effects of the different components of Aβ1–42, including monomer (Aβ1–42‐Mono), oligomer (Aβ1–42‐Oligo), and fibril (Aβ1–42‐Fibril), our data confirmed that Aβ1–42‐Oligo is likely to be the most important damage factor that results in TJ damage and BBB leakage in Alzheimer's disease. We found that the incubation of bEnd.3 cells with Aβ1–42 significantly up‐regulated the level of receptor for advanced glycation end‐products (RAGE). Co‐incubation of a polyclonal antibody to RAGE and Aβ1–42‐Oligo in bEnd.3 cells blocked RAGE suppression of Aβ1–42‐Oligo‐induced alterations in TJ scaffold proteins and reversed Aβ1–42‐Oligo‐induced up‐regulation of RAGE, matrix metalloproteinase (MMP)‐2, and MMP‐9. Furthermore, we found that these effects induced by Aβ1–42‐Oligo treatment were effectively suppressed by knockdown of RAGE using small interfering RNA (siRNA) transfection. We also found that GM 6001, a broad‐spectrum MMP inhibitor, partially reversed the Aβ1–42‐Oligo‐induced inhibitor effects in bEnd.3 cells. Thus, these results suggested that RAGE played an important role in Aβ‐induced BBB leakage and alterations of TJ scaffold proteins, through a mechanism that involved up‐regulation of MMP‐2 and MMP‐9. To reveal the role of RAGE in blood–brain barrier (BBB) disruption in Alzheimer's disease (AD), we employed an monolayer BBB model comprising bEnd.3 cell and found that BBB leakage was induced by treatment with amyloid‐β (Aβ), and the levels of tight junction (TJ) scaffold proteins including ZO‐1, Claudin‐5, and Occludin were decreased. Using receptor for advanced glycation end‐products (RAGE) neutralizing polyclonal antibody and siRNA, we confirmed that RAGE played an important role in Aβ‐induced BBB leakage and alterations of TJ scaffold proteins and in the up‐regulation of matrix metalloproteinase‐2 (MMP‐2) and matrix metalloproteinase‐9 (MMP‐9). NF‐κB, nuclear factor kappa‐light‐chain‐enhancer of activated B cells.

Local perfusion of capillaries reveals disrupted beta-amyloid homeostasis at the blood-brain barrier in Tg2576 murine Alzheimer's model

The Effect of Chronic Cerebral Hypoperfusion on Amyloid-β Metabolism in a Transgenic Mouse Model of Alzheimer's Disease (PS1V97L).

The Effect of Chronic Cerebral Hypoperfusion on Blood-Brain Barrier Permeability in a Transgenic Alzheimer’s Disease Mouse Model (PS1V97L)1

Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice

Retinal capillary degeneration and blood-retinal barrier disruption in murine models of Alzheimer’s disease

TNF-α and IL-1β Modulate Blood-Brain Barrier Permeability and Decrease Amyloid-β Peptide Efflux in a Human Blood-Brain Barrier Model

Cerebrovascular Dysfunction in Amyloid Precursor Protein Transgenic Mice: Contribution of Soluble and Insoluble Amyloid-Beta Peptide, Partial Restoration Via Gamma-Secretase Inhibition

Amyloid beta accumulation in TgF344-AD rats is associated with reduced cerebral capillary endothelial Kir2.1 expression and neurovascular uncoupling

Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease.

Deletion Ofabca7increases Cerebral Amyloid-β Accumulation in the J20 Mouse Model of Alzheimer's Disease

Altered dynamics of glymphatic flow in a mature-onset Tet-off APP mouse model of amyloidosis

Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells

Murine Beta-Amyloid (1–42) Oligomers Disrupt Endothelial Barrier Integrity and VEGFR Signaling via Activating Astrocytes to Release Deleterious Soluble Factors

A Chronic Increase in Blood-Brain Barrier Permeability Facilitates Intraneuronal Deposition of Exogenous Bloodborne Amyloid-Beta1–42 Peptide in the Brain and Leads to Alzheimer's Disease-Relevant Cognitive Changes in a Mouse Model

Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease

Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer Aβ Peptides

Aβ1–42 oligomer‐induced leakage in an in vitro blood–brain barrier model is associated with up‐regulation of RAGE and metalloproteinases, and down‐regulation of tight junction scaffold proteins

Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation

P2‐347: Absence of MDR‐1 P‐glycoprotein at the Blood‐brain Barrier Increased the Passage of Blood‐borne Exogenous Aβ Peptides Across the BBB into the Brain

Increased soluble amyloid-beta causes early aberrant brain network hypersynchronisation in a mature-onset mouse model of amyloidosis

Quantitative Study of the Capillaries Within the White Matter of the Tg2576 Mouse Model of Alzheimer's Disease.